Sanofi and GlaxoSmithKline have agreed a deal with the European Commission to provide up to 300 million doses of their potential COVID-19 vaccine candidate. According to GSK, the EU will provide upfront funding to support the scale-up of the companies’ manufacturing capabilities in Europe. The final agreement marks a key milestone in protecting the EU population from COVID-19. Source: Pharmatimes 23/09/2020